Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameSodium bicarbonate
Accession NumberDB01390
Typesmall molecule
Groupsapproved
Description

Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

Structure
Thumb
Synonyms
SynonymLanguageCode
Baking sodaNot AvailableNot Available
Bicarbonate of sodaNot AvailableNot Available
Carbonic acid monosodium saltNot AvailableNot Available
Sodium acid carbonateNot AvailableNot Available
Sodium hydrogen carbonateNot AvailableNot Available
Sodium hydrogencarbonateNot AvailableNot Available
SaltsNot Available
Brand namesNot Available
Brand mixtures
Brand NameIngredients
Alka-Seltzer FlavouredAcetylsalicylic Acid + Citric Acid + Sodium Bicarbonate
Amo Endosol Extraalcium Chloride + Dextrose + Glutathione Disulfide + Magnesium Chloride + Potassium Chloride + Sodium Bicarbonate + Sodium Chloride + Sodium Phosphate Dibasic
ArtrolAntipyrine + Cimicifuga Racemosa + Methyl Salicylate + Sodium Bicarbonate + Sodium Salicylate + Taraxacum Officinale Weber
Baros Effervescent GranulesSodium Bicarbonate + Tartaric Acid
Bicarbonate Concentrate D16000Sodium Bicarbonate + Sodium Chloride
Bicarbonate Concentrate D16001Sodium Bicarbonate + Sodium Chloride
E-Z-Gas 2Citric Acid + Sodium Bicarbonate
Woodward's Gripe WaterOil of Dill + Sodium Bicarbonate
CategoriesNot Available
CAS number144-55-8
WeightAverage: 84.0066
Monoisotopic: 83.982338573
Chemical FormulaCHNaO3
InChI KeyInChIKey=UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
IUPAC Name
sodium hydrogen carbonate
SMILES
[Na+].OC([O-])=O
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassOrganic Acids and Derivatives
ClassOrganic Carbonic Acids and Derivatives
SubclassNot Available
Direct parentOrganic Carbonic Acids and Derivatives
Alternative parentsPolyamines
Substituentspolyamine
Classification descriptionThis compound belongs to the organic carbonic acids and derivatives. These are compounds comprising the organic carbonic acid or a derivative thereof.
Pharmacology
IndicationSodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.
PharmacodynamicsIntravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.
Mechanism of actionSodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9292
Blood Brain Barrier + 0.936
Caco-2 permeable - 0.5321
P-glycoprotein substrate Non-substrate 0.8785
P-glycoprotein inhibitor I Non-inhibitor 0.9903
P-glycoprotein inhibitor II Non-inhibitor 0.9931
Renal organic cation transporter Non-inhibitor 0.9563
CYP450 2C9 substrate Non-substrate 0.8326
CYP450 2D6 substrate Non-substrate 0.9017
CYP450 3A4 substrate Non-substrate 0.8144
CYP450 1A2 substrate Non-inhibitor 0.9053
CYP450 2C9 substrate Non-inhibitor 0.9337
CYP450 2D6 substrate Non-inhibitor 0.9401
CYP450 2C19 substrate Non-inhibitor 0.9461
CYP450 3A4 substrate Non-inhibitor 0.9774
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9911
Ames test Non AMES toxic 0.9285
Carcinogenicity Non-carcinogens 0.5181
Biodegradation Ready biodegradable 0.9636
Rat acute toxicity 1.9204 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9596
hERG inhibition (predictor II) Non-inhibitor 0.9866
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Abbott laboratories pharmaceutical products div
Packagers
Dosage forms
FormRouteStrength
LiquidOral
PowderOral
SolutionIntravenous
Solution / dropsOral
TabletOral
Prices
Unit descriptionCostUnit
Golytely 236 gm Solution28.0USDbottle
Colyte 240 gm Solution26.0USDbottle
Golytely 227.1 gm Solution Packet21.85USDpacket
Colyte-Flavored 240 gm Solution18.17USDbottle
Elliotts b solution ampule4.71USDml
Sodium bicarb 4.2% vial1.45USDml
Neut 4% vial0.92USDml
Bss plus eye solution0.2USDml
Sodium bicarb 650 mg tablet0.07USDtablet
Antacid 650 mg tablet0.05USDtablet
Antacid 325 mg tablet0.04USDtablet
Sodium bicarb 325 mg tablet0.04USDtablet
Sodium bicarb 7.5% vial0.04USDml
Sodium bicarbonate powder0.03USDg
Sodium bicarb 8.4% vial0.02USDml
Sodium bicarbonate 5% inj0.02USDml
Colyte with flavor packets0.01USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting pointDecomposes around 50 °CNot Available
water solubility1E+005 mg/L (at 25 °C)MERCK INDEX (1996)
pKa6.3Not Available
Predicted Properties
PropertyValueSource
water solubility7.64e+02 g/lALOGPS
logP-0.06ALOGPS
logP0.25ChemAxon
logS0.96ALOGPS
pKa (strongest acidic)6.05ChemAxon
physiological charge-1ChemAxon
hydrogen acceptor count3ChemAxon
hydrogen donor count1ChemAxon
polar surface area60.36ChemAxon
rotatable bond count0ChemAxon
refractivity20.34ChemAxon
polarizability3.86ChemAxon
number of rings0ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Alan B. Gancy, Rustom P. Poncha, “Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream.” U.S. Patent US3984527, issued August, 1922.

US3984527
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD01203
KEGG CompoundC12603
PubChem Compound516892
PubChem Substance46507049
ChemSpider8609
ChEBI32139
ChEMBLCHEMBL1353
Therapeutic Targets DatabaseDAP000128
PharmGKBPA451375
Drug Product Database2280884
RxListhttp://www.rxlist.com/cgi/generic/sodbic.htm
Drugs.comhttp://www.drugs.com/cdi/sodium-bicarbonate.html
WikipediaSodium_bicarbonate
ATC CodesB05XA02B05CB04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(74 KB)
Interactions
Drug Interactions
Drug
AtazanavirThis gastric pH modifier decreases the levels/effect of atazanavir
BenzphetamineAlkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered.
DeferiproneDeferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
EltrombopagLevels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
LithiumThe urine alkalizer decreases the effect of lithium
MemantinePossible increased levels of memantine
Methenamine mandelateUrine alkalizer decreases the effect of methenamine
QuinidineThe antacid increases the effect of quinidine
TiclopidineSodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart.
TipranavirSodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir.
TrandolaprilSodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced.
Food InteractionsNot Available

1. Hydrogen ions

Kind: small molecule

Organism:

Pharmacological action: yes

Actions: neutralizer

Components

Name UniProt ID Details

References:

  1. Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. Pubmed
  2. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. Pubmed
  3. Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. Pubmed
  4. Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. Pubmed
  5. Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. Pubmed

1. Electrogenic sodium bicarbonate cotransporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Electrogenic sodium bicarbonate cotransporter 1 Q9Y6R1 Details

References:

  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. Pubmed
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. Pubmed
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. Pubmed
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. Pubmed

2. Sodium bicarbonate cotransporter 3

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sodium bicarbonate cotransporter 3 Q9Y6M7 Details

References:

  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. Pubmed
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. Pubmed
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. Pubmed
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. Pubmed

3. Electroneutral sodium bicarbonate exchanger 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Electroneutral sodium bicarbonate exchanger 1 Q2Y0W8 Details

References:

  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. Pubmed
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. Pubmed
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. Pubmed
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. Pubmed

4. Electrogenic sodium bicarbonate cotransporter 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Electrogenic sodium bicarbonate cotransporter 4 Q9BY07 Details

References:

  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. Pubmed
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. Pubmed
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. Pubmed
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. Pubmed

5. Sodium-driven chloride bicarbonate exchanger

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sodium-driven chloride bicarbonate exchanger Q6U841 Details

References:

  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. Pubmed
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. Pubmed
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. Pubmed
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. Pubmed

Comments
Drug created on July 08, 2007 10:59 / Updated on September 16, 2013 17:14